Introduction
Tumor growth and metastasis often depends on the elaboration of new capillary blood vessels, a process called angiogenesis (1) . Angiogenesis inhibitors primarily target the proliferation and migration of endothelial cells, providing a complimentary approach, along with direct tumor cytotoxic chemotherapy, for treating cancer (2) .
Angiostatin is an approximately 38 kDa protein derived from an internal fragment of plasminogen (3) which suppresses the growth of experimental tumors in animal models (4) . Angiostatin was originally purified from the urine of mice with Lewis lung carcinoma (3) and is generated endogenously by a variety of human tumors as well (5, 6) . The conversion of plasminogen to angiostatin appears to require reduction of disulfide bonds followed by proteolysis with one or more proteinases (7, 8) .
Angiostatin has been observed to inhibit endothelial (3) and smooth muscle cell (9) proliferation by disrupting the G2/M transition in the cell cycle progression (10) . Angiostatin has also been shown to induce apoptosis of HUVEC (11) . Angiostatin may have an even more potent inhibitory effect on circulating, bone-marrow derived endothelial progenitor cells than it has on mature endothelial cells (12) . However, the molecular mechanisms of the antiangiogenesis effect of angiostatin have not been completely elucidated.
Angiostatin binds to the endothelial cell surface F1-Fo ATP synthase, where it blocks both the ATP synthase and ATPase activities of this enzyme complex (13, 14) . The anti-angiogenic effects of angiostatin may also be mediated via only.
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Angiostatin has similarities with hepatocyte growth factor (HGF;"scatter factor"), an angiogenic growth factor that acts as a mitogen and motogen for endothelial cells and smooth muscle cells. Although they have opposing effects on angiogenesis, both HGF and angiostatin possess kringle motifs (18,19) and share significant homology at the amino acid level (19) . We have previously shown that angiostatin inhibits HGF-induced smooth muscle cell proliferation and migration, suggesting that angiostatin might competitively inhibit the binding of HGF to its receptor, c-met proto-oncogene (9) . In this paper, we examine this hypothesis and demonstrate that angiostatin inhibits signaling events induced by HGF but not by VEGF or bFGF. Iodobeads and the Super Signal chemiluminescence kit were purchased from Pierce Chemical Co (Rockford, IL). Alkaline phosphatase activity was detected using the soluble substrate p-nitrophenylphosphate with diethanolamine buffer from BIORAD (Hercules, CA).
Cell culture:
HUVEC and HASMC were purchased from Clonetics Corp. (Walkersville, MD).
HUVEC were maintained in EGM-2 medium containing growth factors, 2% FBS, 50 g/ml gentamicin and 50 g/ml of amphotericin. Human aortic smooth muscle cells (HASMC) were maintained in SmGM-2 medium containing growth factors, 5% FBS and 50 g/ml gentamicin. A431 (human epidermoid carcinoma cells), obtained from ATCC (Manassas, VA) were grown in modified DMEM medium containing 10% FBS. S180 and A549 were also cultured in DMEM + 10% FBS .
MCF-7 and BT474 cells were grown in RPMI + 10% FBS was used. For soluble c-met studies, DMEM or RPMI were used without FBS.
Treatment of cells:
HUVEC and HASMC were seeded in 60 mm tissue culture plates and were grown in EGM-2 and SmGM-2 complete medium, respectively, to 90% confluence, then incubated overnight in SmGM and EGM-2 serum free medium. tissue culture dishes and grown in complete medium to near 100% confluency.
Cells were washed with PBS and serum free medium was added to the plate.
After 16 hours, the medium was harvested (7.0 mls), protease inhibitor cocktail was added and centrifuged at 10,000 x g at 4 0 C for 1 hour to remove any cell debris. The supernatant was filtered through a 0.22 m filter and concentrated by using centriprep 10 (cut off 10,000 kDa) at 3000 X g until the volume was reduced to 0.5 ml. The concentrated medium (35 µl) was mixed with 35 µl of 2X sample buffer (reducing or non-reducing) then boiled for 3 minutes and subjected to SDS-PAGE (7.5% gels).
Cell proliferation assay HUVEC (5,000 cells per well) were cultured in a 96 well plate in EBM-2 medium containing 1.0% serum in the presence or absence of HGF (10 ng/ml), bFGF (10 ng/ml) or VEGF (10 ng/ml). Angiostatin, at a final concentration of 3-5 µM was added to replicate wells containing growth factors. 
Enzyme-Linked Immunosorbent Assay
Concentrated A431 serum free medium containing soluble c-met (total protein concentration ~ 4 mg/ml) or Voller's buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 , 0.2% NaN 3 , pH 9.6) was added in triplicate wells to a 96-well EIA/RIA plate (100 µl) and allowed to adsorb overnight at 4 o C. The plates were washed three times with PBS between each step. To block the plates, PBS containing 1% non-fat dry milk was added for 1 hour at room temperature. For a sandwich ELISA, 96-well EIA/RIA plates were incubated overnight with 100 µl of a 1:100 dilution of a monoclonal antibody to the extracellular β-chain of c-met in Voller's buffer. The plates were blocked and concentrated soluble c-met receptor was added.
Angiostatin at concentrations of 0-5 µM in PBS/1% milk was incubated on the plate for 1 hour at room temperature. Anti-human plasminogen at 1:250 dilution was added for 1 hour at room temperature. Alkaline phosphatase-conjugated secondary antibodies (1:250 of anti-rabbit IgG ) were incubated for 1 hour at room temperature. Alkaline phosphatase activity was detected in 1 M diethanolamine (pH 9.8), 0.5 mM MgCl 2 , and 12 mM p-nitrophenyl phosphate.
Plates were read at OD 405 in an ELISA plate reader. The V max was determined using SOFTMAX Pro software (version 2.1.1). In some cases, immunoblots were stripped by incubating the blot at 50 o C for 30 minutes in a buffer containing 62.5 mM Tris-HCl pH 6.7 containing 2% SDS and 100 mM 2-mercaptoethanol. The blot was then washed twice with TBST for 5 min and blocked with 5% milk for 30 minutes at room temp followed by a washing twice with TBST for 5 min, the re-probing with a primary antibody as described. (Fig 11A) . Hepatocyte growth factor was able to inhibit 125 Iangiostatin binding to HUVEC (Fig 11B) .
We examined the production of soluble c-met by 5 tumor cell lines. A431
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